As the proportion of our population with chronic wound care problems continues to grow, there is an increasing need to develop therapies that both accelerate repair and decrease the rate of wound recurrence. The topical application of single recombinant growth factors to the chronic wound has not lived up to initial expectations, with only one factor currently being considered for release onto the market. This paper discusses the growing problem of the chronic wound, possible reasons for the failure of recombinant growth factors to yield significant clinical outcomes, and describes a new approach to the isolation and delivery of a mixture of growth factors for chronic wound repair.
|Number of pages
|Published - 1 Jan 1997